Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 119

1.

JC viruria associates with reduced risk of diabetic kidney disease.

Kruzel-Davila E, Divers J, Russell GB, Kra-Oz Z, Szwarcwort Cohen M, Langefeld CD, Ma L, Lyles DS, Hicks PJ, Skorecki KL, Freedman BI.

J Clin Endocrinol Metab. 2019 Jan 30. doi: 10.1210/jc.2018-02482. [Epub ahead of print]

PMID:
30715336
2.

Protective association between JC polyoma viruria and kidney disease.

Divers J, Langefeld CD, Lyles DS, Ma L, Freedman BI.

Curr Opin Nephrol Hypertens. 2019 Jan;28(1):65-69. doi: 10.1097/MNH.0000000000000464.

PMID:
30320619
3.

Immunogenicity in African Green Monkeys of M Protein Mutant Vesicular Stomatitis Virus Vectors and Contribution of Vector-Encoded Flagellin.

Westcott MM, Smedberg J, Jorgensen MJ, Puckett S, Lyles DS.

Vaccines (Basel). 2018 Mar 19;6(1). pii: E16. doi: 10.3390/vaccines6010016.

4.

JC polyoma viruria associates with protection from chronic kidney disease independently from apolipoprotein L1 genotype in African Americans.

Freedman BI, Kistler AL, Skewes-Cox P, Ganem D, Spainhour M, Turner J, Divers J, Langefeld CD, Murea M, Hicks PJ, Hemal AK, Snipes JA, Zhao L, Abend JR, Lyles DS, Ma L, Skorecki KL.

Nephrol Dial Transplant. 2018 Nov 1;33(11):1960-1967. doi: 10.1093/ndt/gfx368.

PMID:
29420808
5.

Migration of Nucleocapsids in Vesicular Stomatitis Virus-Infected Cells Is Dependent on both Microtubules and Actin Filaments.

Yacovone SK, Smelser AM, Macosko JC, Holzwarth G, Ornelles DA, Lyles DS.

J Virol. 2016 Jun 10;90(13):6159-70. doi: 10.1128/JVI.00488-16. Print 2016 Jul 1.

6.

The border-to-border distribution method for analysis of cytoplasmic particles and organelles.

Yacovone SK, Ornelles DA, Lyles DS.

Cell Tissue Res. 2016 Feb;363(2):351-60. doi: 10.1007/s00441-015-2265-x. Epub 2015 Aug 28.

7.

Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.

Westcott MM, Liu J, Rajani K, D'Agostino R Jr, Lyles DS, Porosnicu M.

J Virol. 2015 Aug;89(15):7944-54. doi: 10.1128/JVI.00757-15. Epub 2015 May 20.

8.

Changes in Susceptibility to Oncolytic Vesicular Stomatitis Virus during Progression of Prostate Cancer.

Yu N, Puckett S, Antinozzi PA, Cramer SD, Lyles DS.

J Virol. 2015 May;89(10):5250-63. doi: 10.1128/JVI.00257-15. Epub 2015 Mar 4.

9.

Molecular determinants of susceptibility to oncolytic vesicular stomatitis virus in pancreatic adenocarcinoma.

Blackham AU, Northrup SA, Willingham M, Sirintrapun J, Russell GB, Lyles DS, Stewart JH 4th.

J Surg Res. 2014 Apr;187(2):412-26. doi: 10.1016/j.jss.2013.10.032. Epub 2013 Oct 21.

10.

Signaling pathways in murine dendritic cells that regulate the response to vesicular stomatitis virus vectors that express flagellin.

Smedberg JR, Westcott MM, Ahmed M, Lyles DS.

J Virol. 2014 Jan;88(2):777-85. doi: 10.1128/JVI.02898-13. Epub 2013 Nov 6.

11.

Preservation of dendritic cell function during vesicular stomatitis virus infection reflects both intrinsic and acquired mechanisms of resistance to suppression of host gene expression by viral M protein.

Westcott MM, Ahmed M, Smedberg JR, Rajani KR, Hiltbold EM, Lyles DS.

J Virol. 2013 Nov;87(21):11730-40. doi: 10.1128/JVI.00680-13. Epub 2013 Aug 28.

12.

Oncolytic vesicular stomatitis virus as a treatment for neuroendocrine tumors.

Randle RW, Northrup SA, Sirintrapun SJ, Lyles DS, Stewart JH 4th.

Surgery. 2013 Dec;154(6):1323-29; discussion 1329-30. doi: 10.1016/j.surg.2013.04.050. Epub 2013 Aug 22.

13.

Comparison of Heterologous Prime-Boost Strategies against Human Immunodeficiency Virus Type 1 Gag Using Negative Stranded RNA Viruses.

Lawrence TM, Wanjalla CN, Gomme EA, Wirblich C, Gatt A, Carnero E, GarcĂ­a-Sastre A, Lyles DS, McGettigan JP, Schnell MJ.

PLoS One. 2013 Jun 26;8(6):e67123. doi: 10.1371/journal.pone.0067123. Print 2013.

14.

Assembly and budding of negative-strand RNA viruses.

Lyles DS.

Adv Virus Res. 2013;85:57-90. doi: 10.1016/B978-0-12-408116-1.00003-3. Review.

PMID:
23439024
15.

Variation in susceptibility of human malignant melanomas to oncolytic vesicular stomatitis virus.

Blackham AU, Northrup SA, Willingham M, D'Agostino RB Jr, Lyles DS, Stewart JH 4th.

Surgery. 2013 Mar;153(3):333-43. doi: 10.1016/j.surg.2012.09.003. Epub 2012 Oct 25.

16.

Complexes of vesicular stomatitis virus matrix protein with host Rae1 and Nup98 involved in inhibition of host transcription.

Rajani KR, Pettit Kneller EL, McKenzie MO, Horita DA, Chou JW, Lyles DS.

PLoS Pathog. 2012 Sep;8(9):e1002929. doi: 10.1371/journal.ppat.1002929. Epub 2012 Sep 27.

17.

Virion-associated complement regulator CD55 is more potent than CD46 in mediating resistance of mumps virus and vesicular stomatitis virus to neutralization.

Johnson JB, Lyles DS, Alexander-Miller MA, Parks GD.

J Virol. 2012 Sep;86(18):9929-40. doi: 10.1128/JVI.01154-12. Epub 2012 Jul 3.

18.

Vesicular stomatitis virus as a treatment for colorectal cancer.

Stewart JH 4th, Ahmed M, Northrup SA, Willingham M, Lyles DS.

Cancer Gene Ther. 2011 Dec;18(12):837-49. doi: 10.1038/cgt.2011.49. Epub 2011 Sep 2.

19.

Interplay between innate immunity and negative-strand RNA viruses: towards a rational model.

Gerlier D, Lyles DS.

Microbiol Mol Biol Rev. 2011 Sep;75(3):468-90, second page of table of contents. doi: 10.1128/MMBR.00007-11. Review.

20.
21.

Stimulation of human dendritic cells by wild-type and M protein mutant vesicular stomatitis viruses engineered to express bacterial flagellin.

Ahmed M, Puckett S, Arimilli S, Braxton CL, Mizel SB, Lyles DS.

J Virol. 2010 Nov;84(22):12093-8. doi: 10.1128/JVI.00406-10. Epub 2010 Sep 15.

22.

Susceptibility of breast cancer cells to an oncolytic matrix (M) protein mutant of vesicular stomatitis virus.

Ahmed M, Puckett S, Lyles DS.

Cancer Gene Ther. 2010 Dec;17(12):883-92. doi: 10.1038/cgt.2010.46. Epub 2010 Aug 20.

23.

Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens.

Braxton CL, Puckett SH, Mizel SB, Lyles DS.

J Virol. 2010 Apr;84(7):3552-61. doi: 10.1128/JVI.01572-09. Epub 2010 Jan 20.

24.

Interferon response and viral evasion by members of the family rhabdoviridae.

Faul EJ, Lyles DS, Schnell MJ.

Viruses. 2009 Dec;1(3):832-51. doi: 10.3390/v1030832. Epub 2009 Nov 9.

25.

Assembly of arenavirus envelope glycoprotein GPC in detergent-soluble membrane microdomains.

Agnihothram SS, Dancho B, Grant KW, Grimes ML, Lyles DS, Nunberg JH.

J Virol. 2009 Oct;83(19):9890-900. doi: 10.1128/JVI.00837-09. Epub 2009 Jul 22.

26.

Vesicular stomatitis virus induces apoptosis primarily through Bak rather than Bax by inactivating Mcl-1 and Bcl-XL.

Pearce AF, Lyles DS.

J Virol. 2009 Sep;83(18):9102-12. doi: 10.1128/JVI.00436-09. Epub 2009 Jul 8.

27.

Vesicular stomatitis virus M protein mutant stimulates maturation of Toll-like receptor 7 (TLR7)-positive dendritic cells through TLR-dependent and -independent mechanisms.

Ahmed M, Mitchell LM, Puckett S, Brzoza-Lewis KL, Lyles DS, Hiltbold EM.

J Virol. 2009 Apr;83(7):2962-75. doi: 10.1128/JVI.02030-08. Epub 2009 Jan 14.

28.

Vesicular stomatitis virus matrix protein mutations that affect association with host membranes and viral nucleocapsids.

Dancho B, McKenzie MO, Connor JH, Lyles DS.

J Biol Chem. 2009 Feb 13;284(7):4500-9. doi: 10.1074/jbc.M808136200. Epub 2008 Dec 16.

29.

hnRNPs Relocalize to the cytoplasm following infection with vesicular stomatitis virus.

Pettit Kneller EL, Connor JH, Lyles DS.

J Virol. 2009 Jan;83(2):770-80. doi: 10.1128/JVI.01279-08. Epub 2008 Nov 12.

30.

Early steps of the virus replication cycle are inhibited in prostate cancer cells resistant to oncolytic vesicular stomatitis virus.

Carey BL, Ahmed M, Puckett S, Lyles DS.

J Virol. 2008 Dec;82(24):12104-15. doi: 10.1128/JVI.01508-08. Epub 2008 Oct 1.

31.

Immune response in the absence of neurovirulence in mice infected with m protein mutant vesicular stomatitis virus.

Ahmed M, Marino TR, Puckett S, Kock ND, Lyles DS.

J Virol. 2008 Sep;82(18):9273-7. doi: 10.1128/JVI.00915-08. Epub 2008 Jul 9.

32.
33.

New mRNAs are preferentially translated during vesicular stomatitis virus infection.

Whitlow ZW, Connor JH, Lyles DS.

J Virol. 2008 Mar;82(5):2286-94. Epub 2007 Dec 19.

35.

Antiviral activity and RNA polymerase degradation following Hsp90 inhibition in a range of negative strand viruses.

Connor JH, McKenzie MO, Parks GD, Lyles DS.

Virology. 2007 May 25;362(1):109-19. Epub 2007 Jan 26.

36.

Oncolytic vesicular stomatitis virus induces apoptosis via signaling through PKR, Fas, and Daxx.

Gaddy DF, Lyles DS.

J Virol. 2007 Mar;81(6):2792-804. Epub 2006 Dec 27.

37.

Preferential translation of vesicular stomatitis virus mRNAs is conferred by transcription from the viral genome.

Whitlow ZW, Connor JH, Lyles DS.

J Virol. 2006 Dec;80(23):11733-42. Epub 2006 Sep 27.

38.
42.
43.

The disintegrin echistatin stabilizes integrin alphaIIbbeta3's open conformation and promotes its oligomerization.

Hantgan RR, Stahle MC, Connor JH, Lyles DS, Horita DA, Rocco M, Nagaswami C, Weisel JW, McLane MA.

J Mol Biol. 2004 Oct 1;342(5):1625-36.

PMID:
15364586
44.
50.

Ligand binding promotes the entropy-driven oligomerization of integrin alpha IIb beta 3.

Hantgan RR, Lyles DS, Mallett TC, Rocco M, Nagaswami C, Weisel JW.

J Biol Chem. 2003 Jan 31;278(5):3417-26. Epub 2002 Nov 7.

Supplemental Content

Loading ...
Support Center